Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | LCK | P06239 | 9/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 3/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733780 | 0.92 | HDAC1 (0.61) | HDAC1LCKSCD | |
| SCHEMBL210651 | 0.90 | HDAC1 (0.64) | HDAC1LCKSCD | |
| SCHEMBL211848 | 0.88 | HDAC1 (0.56) | HDAC1LCKDYRK1ASCD | |
| SCHEMBL212264 | 0.86 | HDAC1 (0.61) | HDAC1LCKSCD | |
| SCHEMBL2733518 | 0.86 | HDAC1 (0.58) | HDAC1LCKDYRK1ASCD | |
| SCHEMBL210833 | 0.85 | AURKB (0.60) | HDAC1LCKSCD | |
| SCHEMBL210213 | 0.83 | HDAC1 (0.81) | HDAC1DYRK1ADYRK1BSCD | |
| SCHEMBL209892 | 0.82 | HDAC1 (0.68) | HDAC1 | |
| SCHEMBL5584436 | 0.80 | KMT2A (0.51) | HDAC1DYRK1A | |
| SCHEMBL210488 | 0.79 | HDAC1 (0.64) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885LCK 1674/4885DYRK1A 3424/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885LCK 1429/4885DYRK1A 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.